Coronado Biosciences, a biopharmaceutical company based in Burlington, Mass., has announced that it has enrolled in TRUST-1, phase 2 of its clinical trial of TSO for Chrohn's disease.
The clinical trial of TSO, Trichuris suis ova or CNDO-201, will be a randomized, double-blind, placebo-controlled, multicenter study involving 250 Chrohn's disease patents.
More Articles on Gastroenterology:
14 Top Symptoms Leading to Gastroenterology Outpatient Visits
Dr. Carol-Lee Collins Joins KRMC in Arizona
La Peer Health Systems Launches Barrett's Esophagus Center of Excellence